Filter
25
Filtered Results: 25
Text search:
Fairlie,
L.
Featured
Recommendations
6
Language
Document type
No document type
11
Guidelines
10
Studies & Reports
4
Countries / Regions
Brazil
2
Thailand
1
Ukraine
1
Rwanda
1
Global
1
Authors & Publishers
Publication Years
Category
COVID-19
2
Guidelines
2
Demograhic Health Surveys DHS
1
Toolboxes
Children & Adolescents
4
Vaxzevria (Astra Zeneca)
4
Drug resistance
3
Infection Control General
3
Educational Settings
3
Workplace
3
Physical Distancing
3
ART Drug Resistance
2
Treatment & Prevention
2
General Reports
1
Clinical Aspects, Treatment & Prevention
1
HIV testing & disclosure
1
Children/Adolescents Mental Disorders
1
Adherence
1
Prevention & Preparedness
1
Universal Health Coverage UHC and 90-90-90 Strategy
1
Country specific documents
1
Global Impact: Socio-economic, health services, TB & HIV
1
Non-pharmaceutical interventions (NPIs)
1
TB/HIV
1
Booster Doses
1
HIV and coinfection
1
TB/HIV Coinfection
1
Reports & Studies Children HIV
1
Reports & Studies
1
Eastern Europe and central Asia
1
Recommendations, resources and references
A publication of the Southern African HIV Clinicians Society
orientations provisoires, 14 juin 2021
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
Frontiers in Pediatrics | www.frontiersin.org
1 April 2019 | Volume 7 | Article 159
PLOS ONE | DOI:10.1371/journal.pone.0172392 February 16, 2017
Avec l’essor des traitements antirétroviraux (TAR) à base de dolutégravir (DTG) pour soigner les personnes vivant avec
le VIH dans le monde, il est important d’estimer la vitesse à laquelle la résistance acquise au DTG apparaît dans les
populations sous TAR. Bien que la résistance au DT...
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
F1000Research 2019, 8:323 Last updated: 17 MAY 2019
Research Article
PLOS ONE | https://doi.org/10.1371/journal.pone.0192791 February 15, 2018
A medida que el tratamiento antirretrovírico con dolutegravir se extiende a más personas que viven con el VIH en el
mundo, adquiere más importancia estimar la frecuencia con que surge la farmacorresistencia adquirida a este
antirretrovírico en las poblaciones tratadas con esquemas que lo conti...
WHO’s sentinel surveys of acquired HIV resistance to dolutegravir among people receiving dolutegravir-containing antiretroviral therapy is intended for easy and frequent implementation. Results from sentinel surveys provide insight into the prevalence and year-over-year trends of dolutegravir resi...
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
Interim guidance, 26 October 2021
This interim guidance has been developed on the basis of the advice issued by the Strategic Advisory Group of Experts (SAGE) on Immunization at its meeting on 5 October 2021.
SAGE said moderately and severely immunocompromised persons should be offered an addition...
Consideraciones para aplicar y ajustar medidas de salud pública y sociales en el contexto de la COVID-19
recommended
orientaciones provisionales, 14 de junio de 2021
Considerations for implementing and adjusting public health and social measures in the context of COVID-19
recommended
interim guidance, 14 June 2021
This document is intended for national authorities and decision makers in countries that have introduced large scale public health and social measures. It offers guidance for adjusting public health and social measures, while managing the risk of a resurgence of cases...
Why bold action against inequalities is needed to en AIDS, stop COVID-19 and prepare for future pandemics
Considerations on the implementation and adjustment of
public health and social measures in the context of
COVID-19
Interim guidance 14 June 2021
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
